论文部分内容阅读
目的:分析39例中晚期胃癌患者动静脉联合化疗的治疗效果及影响因素、探讨其治疗策略的选择。方法:本组病例动静脉化疗联合应用的顺序一般是先行动脉化疗2周期,然后行全身静脉化疗3～4周期,病情稳定后改为中医中药及口服化疗药或免疫治疗。结果:有35例达到症状完全消失,肿瘤显著缩小26%(PR:13/39),肿瘤中度缩小51%,18例患者肿瘤标志物下降50%以上,4例患者完全降至正常,半年生存率90%,1年生存率56%,3年生存率33%,5年生存率10%。结论:中晚期胃癌患者采用动静脉联合化疗+栓塞治疗,不但切实可行,而且并发症少,能使部分患者达到Ⅱ期手术切除,减少或延缓患者的转移和复发,提高患者的生活质量,延长生存时间。
Objective: To analyze the therapeutic effect and influencing factors of arteriovenous combined chemotherapy in 39 patients with advanced gastric cancer and to explore the choice of treatment strategy. Methods: The combined application of arteriovenous chemotherapy in this group of patients is generally followed by the first two cycles of arterial chemotherapy, and then three to four cycles of systemic intravenous chemotherapy, stable condition and changed to traditional Chinese medicine and oral chemotherapy drugs or immunotherapy. RESULTS: Thirty-five patients achieved a complete disappearance of symptoms with a significant 26% reduction in tumor size (PR 13/39), a moderate reduction of 51% in tumor size, a 50% reduction in tumor markers in 18 patients, a complete reduction in 4 patients to normal, Survival rate of 90%, 1-year survival rate of 56%, 3-year survival rate of 33%, 5-year survival rate of 10%. Conclusion: The use of arteriovenous plus chemoembolization and embolization in advanced gastric cancer patients is not only feasible but also has fewer complications, which can make some patients reach stage Ⅱ resection, reduce or delay the metastasis and recurrence of patients, improve the quality of life and prolong the life of patients Survival time.